Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Justin M Watts,Maria R Baer,Jay Yang,Thomas Prebet,Sangmin Lee,Gary J Schiller,Shira N Dinner,Arnaud Pigneux,Pau Montesinos,Eunice S Wang,Karen P Seiter,Andrew H Wei,Stephane De Botton,Montserrat Arnan,Will Donnellan,Anthony P Schwarer,Christian Récher,Brian A Jonas,P Brent Ferrell,Christophe Marzac,Patrick Kelly,Jennifer Sweeney,Sanjeev Forsyth,Sylvie M Guichard,Julie Brevard,Patrick Henrick,Hesham Mohamed,Jorge E Cortes The Lancet. Haematology（2022）
关键词
acute myeloid leukaemia,myelodysplastic syndrome,azacitidine,olutasidenib
AI 理解论文
溯源树
样例
